Literature DB >> 31612729

PD1+ tumor associated macrophages predict poor prognosis of locally advanced esophageal squamous cell carcinoma.

Yufei Lu1, Leiming Guo1, Gaofeng Ding1.   

Abstract

Aim: Tumor associated macrophages are the most abundant cancer immune cells. However, little was known about the identity of CD68+PD1+ macrophages as well as the contributions in the prognosis of esophageal squamous cell carcinoma (ESCC). Methods & methods: Immunofluorescence, flowcytometry and RT-PCR were used to analysis PD1+ macrophages in ESCC.
Results: CD68+PD1+ macrophages which can express higher M2 markers in cancer tissues, increased about 4.2-times compared with para-cancer tissues. Additionally, PD1high macrophages were significantly correlated with more malignant phenotypes and poor prognosis. PD1 treatment can enhance phagocytosis of cultured macrophages and redirect this macrophage to M1-like phenotype.
Conclusion: Thus, our findings overall indicate that CD68+PD1+ macrophages are tumor associated macrophagess in ESCC, which can forecast the prognosis of ESCC.

Entities:  

Keywords:  CD68; PD1; esophageal squamous cell carcinoma; prognosis; tumor-associated macrophage

Mesh:

Substances:

Year:  2019        PMID: 31612729     DOI: 10.2217/fon-2019-0519

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  6 in total

1.  Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma.

Authors:  Xiang Zhou; Junlong Wu; Chunguang Duan; Yingjie Liu
Journal:  J Immunol Res       Date:  2020-10-01       Impact factor: 4.818

2.  An Extracellular Matrix-Based Signature Associated With Immune Microenvironment Predicts the Prognosis and Therapeutic Responses of Patients With Oesophageal Squamous Cell Carcinoma.

Authors:  Hongpan Zhang; Qi Shi; Zhihao Yang; Kaige Wang; Zhiyu Zhang; Zheng Huang; Xiaobin Cui; Feng Li
Journal:  Front Mol Biosci       Date:  2021-03-18

Review 3.  Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?

Authors:  Michael Kuske; Maximilian Haist; Thomas Jung; Stephan Grabbe; Matthias Bros
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

4.  Tumor-associated macrophage (TAM)-derived CCL22 induces FAK addiction in esophageal squamous cell carcinoma (ESCC).

Authors:  Jie Chen; Di Zhao; Lingyuan Zhang; Jing Zhang; Yuanfan Xiao; Qingnan Wu; Yan Wang; Qimin Zhan
Journal:  Cell Mol Immunol       Date:  2022-08-12       Impact factor: 22.096

5.  High expression of HNRNPR in ESCA combined with 18F-FDG PET/CT metabolic parameters are novel biomarkers for preoperative diagnosis of ESCA.

Authors:  Xiao-Yu Liu; Yan Gao; Xue-Yan Kui; Xu-Sheng Liu; Yao-Hua Zhang; Yu Zhang; Chang-Bin Ke; Zhi-Jun Pei
Journal:  J Transl Med       Date:  2022-10-04       Impact factor: 8.440

6.  Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth.

Authors:  Le Qin; Ruocong Zhao; Dongmei Chen; Xinru Wei; Qiting Wu; Youguo Long; Zhiwu Jiang; Yangqiu Li; Haipeng Wu; Xuchao Zhang; Yilong Wu; Shuzhong Cui; Wei Wei; Huihui Yao; Zixia Liu; Su Cao; Yao Yao; Zhenfeng Zhang; Peng Li
Journal:  Biomark Res       Date:  2020-06-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.